Key result
Antiplatelet review outlines stroke epidemiology and management without reporting specific quantitative findings.
Why the study?
Do antiplatelet drugs prevent recurrent stroke in patients with acute ischaemic stroke?
Do antiplatelet drugs prevent recurrent stroke in patients with acute ischaemic stroke?
This text introduces the role of antiplatelet drugs in the secondary prevention of stroke.
Answers are grounded in this paper and cite their sources.
Offers no quantitative data on antiplatelet efficacy; leaves open their role in preventing recurrent ischaemic stroke.
INTRODUCTION Stroke is a major cause of death and disability in developing and developed countries (Murray & Lopez 1996). Incidence rises steeply with age so that about three quarters of incident strokes occur in people over 65 years of age. In community-based studies among whites, around 80% of strokes are ischaemic, while 15% are due to primary intracerebral haemorrhage, and 5% to subarachnoid haemorrhage (Fig. 1). The proportion of haemorrhagic strokes in the mainly non-white populations of Asia and Africa may be somewhat higher, but ischaemic stroke is still the dominant problem (Sudlow & Warlow 1997). The management of patients with acute ischaemic stroke aims to restore tissue perfusion, minimize cytotoxic brain damage and cerebral oedema, prevent complications of stroke, and prevent a recurrent stroke or other serious vascular event. About 10% of patients with a first-ever acute ischaemic stroke die within 30 days of onset. Most of these early
No takes yet. Share an insight, caveat, or question.
Sudlow et al. (2002) conducted a review in Stroke. Antiplatelet Drugs was evaluated. The provided abstract snippet contains only introductory background information on stroke epidemiology and management, reporting no specific quantitative findings for antiplatelet drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: